# Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

> **NCT04003519** · — · WITHDRAWN · sponsor: **Ipsen**

## Conditions studied

- Acromegaly

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04003519
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study timeline delay, low site feasibility and delay concerns due to COVID-19.
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003519, "Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04003519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*